Les thérapies géniques peuvent-elles devenir abordables ?

Abstract

Twenty gene therapies have now been approved in the USA by the FDA, but their stratospheric price tag (often above one million USD per patient) makes them essentially unaffordable for most. A systematic study of the various steps involved in the development and manufacture of these therapies, undertaken (among others) by the Innovative Genomics Institute in California, shows that the cost could be reduced up to tenfold without major legislative changes, and offers hope for affordable genetic therapies.